1 C. R. Wildevuur and J. R. Benfield. A review of 23 human lung transplantations by 20 surgeons.
Ann.Thorac.Surg. 9 (6):489-515, 1970.
2 D. L. Modry, P. E. Oyer, S. W. Jamieson, E. B. Stinson, J. C. Baldwin, B. A. Reitz, K. D. Dawkins, C. G.
McGregor, S. A. Hunt, M. Moran, and . Cyclosporine in heart and heart-lung transplantation. Can.J.Surg. 28 (3):274-80, 282, 1985.
3 O.F.Wagner, A.Haverich. Lungentransplantation. In: Fabel Pneumologie 2nd ed.p 233-247
4 J. M. Smits, J. Vanhaecke, A. Haverich, E. de Vries, M. Smith, E. Rutgrink, A. Ramsoebhag, A. Hop, G. Per-sijn, and G. Laufer. Three-year survival rates for all consecutive heart-only and lung-only transplants per-formed in Eurotransplant, 1997-1999. Clin.Transpl.:89-100, 2003.
5 A. Haverich. Intrathorakale Organtransplantation. In: Fabel 1991
6 A. Haverich. Experience with lung transplantation. Ann.Thorac.Surg. 67 (2):305-312, 1999.
7 Anonymous. International guidelines for the selection of lung transplant candidates. The American Society for Transplant Physicians (ASTP)/American Thoracic Society(ATS)/European Respiratory
Soci-ety(ERS)/International Society for Heart and Lung Transplantation(ISHLT). Am.J.Respir.Crit Care Med. 158 (1):335-339, 1998.
8 J. Niedermeyer, B. Bewig, T. Bickhardt, R. Ewert, P. Fischer, M. Hamm, J. Lill, F. J. Meyer, I. Otterbach, C.
Vogelmeier, F. Wagner, H. Wilkens, and H. Worth. [Lung and heart-lung transplantation. Guidelines for indi-cations and preoperative diagnosis]. Pneumologie 55 (8):396-400, 2001.
9 W. Harringer and A. Haverich. Heart and heart-lung transplantation: standards and improvements. World J.Surg. 26 (2):218-225, 2002.
10 F. Kissmeyer-Nielsen, S. Olsen, V. P. Petersen, and O. Fjeldborg. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 2 (7465):662-665, 1966.
11 A. E. Frost, C. T. Jammal, and P. T. Cagle. Hyperacute rejection following lung transplantation. Chest 110 (2):559-562, 1996.
12 J. C. Scornik, W. Clapp, P. R. Patton, W. J. Van der Werf, A. W. Hemming, A. I. Reed, and R. J. Howard.
Outcome of kidney transplants in patients known to be flow cytometry crossmatch positive. Transplantation 71 (8):1098-1102, 2001.
13 J. Cicciarelli, K. Helstab, and R. Mendez. Flow cytometry PRA, a new test that is highly correlated with graft survival. Clin.Transplant. 6 (3 part 1):159-164, 1992.
14 N. J. Rogers and R. I. Lechler. Allorecognition. Am.J.Transplant. 1 (2):97-102, 2001.
15 Diethard Gemsa, Kalden, Resch. Immunologie. Thieme, p640-654, 1997
16 PhilipT.Cagle. Lung transplant pathology. In: William M. Turlbeck; Andrew M. Charg: .Pathology of the Lung. 2.Aufl. Thieme 827-844, 1995
17 W. A. Wallace, C. O. Bellamy, D. M. Rassl, and D. J. Harrison. Transplant histopathology for the general histopathologist. Histopathology 43 (4):313-322, 2003.
18 R. E. Stanford, S. Ahmed, M. Hodson, N. R. Banner, and M. L. Rose. A role for indirect allorecognition in
lung transplant recipients with obliterative bronchiolitis. Am.J.Transplant. 3 (6):736-742, 2003.
19 J. J. Egan. Obliterative bronchiolitis after lung transplantation: a repetitive multiple injury airway disease.
Am.J.Respir.Crit Care Med. 170 (9):931-932, 2004.
20
S. Sundaresan, T. Mohanakumar, M. A. Smith, E. P. Trulock, J. Lynch, D. Phelan, J. D. Cooper, and G. A.
Patterson. HLA-A locus mismatches and development of antibodies to HLA after lung transplantation corre-late with the development of bronchiolitis obliterans syndrome. Transplantation 65 (5):648-653, 1998.
21 R. J. Keenan, M. E. Lega, J. S. Dummer, I. L. Paradis, J. H. Dauber, H. Rabinowich, S. A. Yousem, R. L.
Hardesty, B. P. Griffith, R. J. Duquesnoy, and . Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation 51 (2):433-438, 1991.
22
A. B. Adams, M. A. Williams, T. R. Jones, N. Shirasugi, M. M. Durham, S. M. Kaech, E. J. Wherry, T.
Onami, J. G. Lanier, K. E. Kokko, T. C. Pearson, R. Ahmed, and C. P. Larsen. Heterologous immunity pro-vides a potent barrier to transplantation tolerance. J.Clin.Invest 111 (12):1887-1895, 2003.
23 M. R. Zamora. Cytomegalovirus and lung transplantation. Am.J.Transplant. 4 (8):1219-1226, 2004.
24 A. L. Girnita, R. Duquesnoy, S. A. Yousem, A. T. Iacono, T. E. Corcoran, M. Buzoianu, B. Johnson, K. J.
Spichty, J. H. Dauber, G. Burckart, B. P. Griffith, K. R. McCurry, and A. Zeevi. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am.J.Transplant. 5 (1):131-138, 2005.
25 W. Chalermskulrat, I. P. Neuringer, W. J. Brickey, N. J. Felix, S. H. Randell, J. P. Ting, and R. M. Aris. Hier-archical contributions of allorecognition pathways in chronic lung rejection. Am.J.Respir.Crit Care Med. 167 (7):999-1007, 2003.
26 W. Chalermskulrat, I. P. Neuringer, J. L. Schmitz, D. J. Catellier, M. J. Gurka, S. H. Randell, and R. M. Aris.
Human leukocyte antigen mismatches predispose to the severity of bronchiolitis obliterans syndrome after lung transplantation. Chest 123 (6):1825-1831, 2003.
27 H. Luckraz, M. Goddard, K. McNeil, C. Atkinson, S. C. Charman, S. Stewart, and J. Wallwork. Microvascular changes in small airways predispose to obliterative bronchiolitis after lung transplantation. J.Heart Lung Transplant. 23 (5):527-531, 2004.
28 T. C. Kotsimbos, G. I. Snell, B. Levvey, D. W. Spelman, A. J. Fuller, S. L. Wesselingh, T. J. Williams, and L.
Ostergaard. Chlamydia pneumoniae serology in donors and recipients and the risk of bronchiolitis obliterans syndrome after lung transplantation. Transplantation 79 (3):269-275, 2005.
29 J. L. Billings, M. I. Hertz, K. Savik, and C. H. Wendt. Respiratory viruses and chronic rejection in lung trans-plant recipients. J.Heart Lung Transtrans-plant. 21 (5):559-566, 2002.
30 P. Borger, H. F. Kauffman, J. Scholma, J. A. Timmerman, and G. H. Koeter. Human allogeneic CD2+ lym-phocytes activate airway-derived epithelial cells to produce interleukin-6 and interleukin-8. Possible role for the epithelium in chronic allograft rejection. J.Heart Lung Transplant. 21 (5):567-575, 2002.
31 C. T. Holweg, W. Weimar, A. G. Uitterlinden, and C. C. Baan. Clinical impact of cytokine gene polymor-phisms in heart and lung transplantation. J.Heart Lung Transplant. 23 (9):1017-1026, 2004.
32 D. Hadjiliadis, Davis R. Duane, M. P. Steele, R. H. Messier, C. L. Lau, S. S. Eubanks, and S. M. Palmer.
Gastroesophageal reflux disease in lung transplant recipients. Clin.Transplant. 17 (4):363-368, 2003.
33 K.Morgenroth „Bronchiolitis obliterans nach Lungentransplantation“ erschienen bei Berlin de Gruyter 1995;
p89-95
34 J. Cairn, T. Yek, N. R. Banner, A. Khaghani, M. E. Hodson, and M. Yacoub. Time-related changes in pulmo-nary function after conversion to tacrolimus in bronchiolitis obliterans syndrome. J.Heart Lung Transplant. 22 (1):50-57, 2003.
35 M. Estenne, J. R. Maurer, A. Boehler, J. J. Egan, A. Frost, M. Hertz, G. B. Mallory, G. I. Snell, and S.
Yousem. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J.Heart Lung Trans-plant. 21 (3):297-310, 2002.
36 F. Meloni, P. Vitulo, A. Cascina, T. Oggionni, A. Bulgheroni, E. Paschetto, C. Klersy, A. M. D'Armini, A.
Fietta, A. M. Bianco, E. Arbustini, and M. Vigano. Bronchoalveolar lavage cytokine profile in a cohort of lung transplant recipients: a predictive role of interleukin-12 with respect to onset of bronchiolitis obliterans syn-drome. J.Heart Lung Transplant. 23 (9):1053-1060, 2004.
37 J. M. Charpin, M. Stern, D. Grenet, and D. Israel-Biet. Insulinlike growth factor-1 in lung transplants with obliterative bronchiolitis. Am.J.Respir.Crit Care Med. 161 (6):1991-1998, 2000.
38 J. W. Kappler, N. Roehm, and P. Marrack. T cell tolerance by clonal elimination in the thymus. Cell 49 (2):273-280, 1987.
39 C. C. Goodnow, J. G. Cyster, S. B. Hartley, S. E. Bell, M. P. Cooke, J. I. Healy, S. Akkaraju, J. C. Rathmell, S. L. Pogue, and K. P. Shokat. Self-tolerance checkpoints in B lymphocyte development. Adv.Immunol.
59:279-368, 1995.
40 I. P. Neuringer, W. Chalermskulrat, and R. Aris. Obliterative bronchiolitis or chronic lung allograft rejection: a basic science review. J.Heart Lung Transplant. 24 (1):3-19, 2005.
41 B. G. Exner, I. N. Acholonu, M. Bergheim, Y. M. Mueller, and S. T. Ildstad. Mixed allogeneic chimerism to induce tolerance to solid organ and cellular grafts. Acta Haematol. 101 (2):78-81, 1999.
42 Lina Lu, Angus W. Thomson. Dendritic cell tolerogenity and prospects for dendritic cell based therapy of allograft rejection and autoimmune disease. In: Michael T. Lotze, Angus W. Thomson Dendritic cells. P448-454 p587-6012.Aufl. Academic Press, 2001
43 L. Brent. The discovery of immunologic tolerance. Hum.Immunol. 52 (2):75-81, 1997.
44 T. E. Starzl. Chimerism and tolerance in transplantation. Proc.Natl.Acad.Sci.U.S.A 101 Suppl 2:14607-14614, 2004.
45 J. J. TRENTIN. Mortality and skin transplantability in x-irradiated mice receiving isologous, homologous or heterologous bone marrow. Proc.Soc.Exp.Biol.Med. 92 (4):688-693, 1956.
46 T. Wekerle. Transplantation tolerance induced by mixed chimerism. J.Heart Lung Transplant. 20 (8):816-823, 2001.
47 R. E. Billingham and L. Brent. A simple method for inducing tolerance of skin homografts in mice.
Trans-plant.Bull. 4 (2):67-71, 1957.
48 R. PAYNE and M. R. ROLFS. Fetomaternal leukocyte incompatibility. J.Clin.Invest 37 (12):1756-1763, 1958.
49 D. J. Triulzi and M. A. Nalesnik. Microchimerism, GVHD, and tolerance in solid organ transplantation.
Transfusion 41 (3):419-426, 2001.
50 J. E. MURRAY, J. P. MERRILL, G. J. DAMMIN, J. B. DEALY, Jr., C. W. WALTER, M. S. BROOKE, and R. E. WILSON. Study on transplantation immunity after total body irradiation: clinical and experimental in-vestigation. Surgery 48:272-284, 1960.
51 Y. Sharabi and D. H. Sachs. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J.Exp.Med. 169 (2):493-502, 1989.
52 M. Sykes and D. H. Sachs. Mixed chimerism. Philos.Trans.R.Soc.Lond B Biol.Sci. 356 (1409):707-726, 2001.
53 K. S. Sivasai, Y. G. Alevy, B. F. Duffy, D. C. Brennan, G. G. Singer, S. Shenoy, J. A. Lowell, T. Howard, and T. Mohanakumar. Peripheral blood microchimerism in human liver and renal transplant recipients: rejection despite donor-specific chimerism. Transplantation 64 (3):427-432, 1997.
54 James HDauber; Adriana Zeevi. Lung transplantation: Local immune function and pulmonary defense mechanisms. Ronald P Daniell M.D.In: Immunology and immunologic disease of the lung.
Boston, Oxford, London p 625-655
55 S. Sakaguchi. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu.Rev.Immunol. 22:531-562, 2004.
56 E. M. Shevach. Regulatory T cells in autoimmmunity*. Annu.Rev.Immunol. 18:423-449, 2000.
57 A. Wu, K. Yamada, C. Baron, D. W. Mathes, L. M. Monajati, P. A. Vagefi, and D. H. Sachs. Detection of regulatory cells as an assay for allograft tolerance in miniature swine. J.Heart Lung Transplant. 23 (2):210-217, 2004.
58 M. A. Gavin, S. R. Clarke, E. Negrou, A. Gallegos, and A. Rudensky. Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo. Nat.Immunol. 3 (1):33-41, 2002.
59 L. Graca, A. Le Moine, C. Y. Lin, P. J. Fairchild, S. P. Cobbold, and H. Waldmann. Donor-specific transplan-tation tolerance: the paradoxical behavior of CD4+CD25+ T cells. Proc.Natl.Acad.Sci.U.S.A 101 (27):10122-10126, 2004.
60 H. Jonuleit, E. Schmitt, M. Stassen, A. Tuettenberg, J. Knop, and A. H. Enk. Identification and functional
characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood.
J.Exp.Med. 193 (11):1285-1294, 2001.
61 C. Baecher-Allan, J. A. Brown, G. J. Freeman, and D. A. Hafler. CD4+CD25high regulatory cells in human peripheral blood. J.Immunol. 167 (3):1245-1253, 2001.
62 W. F. Ng, P. J. Duggan, F. Ponchel, G. Matarese, G. Lombardi, A. D. Edwards, J. D. Isaacs, and R. I. Lechler.
Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood 98 (9):2736-2744, 2001.
63 Y. Kuniyasu, T. Takahashi, M. Itoh, J. Shimizu, G. Toda, and S. Sakaguchi. Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation.
Int.Immunol. 12 (8):1145-1155, 2000.
64 T. E. Starzl, N. Murase, A. J. Demetris, M. Trucco, K. Abu-Elmagd, E. A. Gray, B. Eghtesad, R. Shapiro, A.
Marcos, and J. J. Fung. Lessons of organ-induced tolerance learned from historical clinical experience.
Transplantation 77 (6):926-929, 2004.
65 G. Cordier, H. Garnier, J. P. Clot, P. Camplez, J. P. Gorin, P. Clot, J. P. Rassinier, M. Nizza, and R. Levy.
[Orthotopic liver graft in pigs. 1st results]. Mem.Acad.Chir (Paris) 92 (27):799-807, 1966.
66 I. Buhaescu, L. Segall, D. Goldsmith, and A. Covic. New immunosuppressive therapies in renal transplanta-tion: monoclonal antibodies. J.Nephrol. 18 (5):529-536, 2005.
67 J. M. Borro, Torre M. De la, C. Miguelez, R. Fernandez, D. Gonzalez, and C. Lemos. Comparative Study of Basiliximab Treatment in Lung Transplantation. Transplant.Proc. 37 (9):3996-3998, 2005.
68 C. I. Kingsley, M. Karim, A. R. Bushell, and K. J. Wood. CD25+CD4+ regulatory T cells prevent graft rejec-tion: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J.Immunol. 168 (3):1080-1086, 2002.
69 D. Dieckmann, H. Plottner, S. Berchtold, T. Berger, and G. Schuler. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J.Exp.Med. 193 (11):1303-1310, 2001.
70 L. van Parijs and A. K. Abbas. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280 (5361):243-248, 1998.
71 I. S. Grewal and R. A. Flavell. CD40 and CD154 in cell-mediated immunity. Annu.Rev.Immunol. 16:111-135, 1998.
72 D. M. Rothstein and M. H. Sayegh. T-cell costimulatory pathways in allograft rejection and tolerance. Immu-nol.Rev. 196:85-108, 2003.
73 A. Perniok and A. Rubbert-Roth. [New biological therapeutic options for the treatment of RE: inhibition of costimulatory molecules and blockade of Interleukin-6-interaction]. Z.Rheumatol. 62 (5):433-438, 2003.
74 F. Claas. Chimerism as a tool to induce clinical transplantation tolerance. Curr.Opin.Immunol. 16 (5):578-583, 2004.
75 S. Li, M. Thanikachalam, M. Pang, M. Carreno, A. Aitouche, and S. M. Pham. Combined host-conditioning with CTLA4-Ig, tacrolimus, anti-lymphocyte serum, and low-dose radiation leads to stable mixed hematopoi-etic chimerism. Exp.Hematol. 29 (4):534-541, 2001.
76 A. I. Scott, L. D. Sharples, and S. Stewart. Bronchiolitis obliterans syndrome : risk factors and therapeutic strategies. Drugs 65 (6):761-771, 2005.
77 A. B. Cosimi. Calcineurin inhibitors are not antagonistic to tolerance induction. Transplant.Proc. 34 (5):1376-1377, 2002.
78 C. Knoop, A. Haverich, and S. Fischer. Immunosuppressive therapy after human lung transplantation.
Eur.Respir.J. 23 (1):159-171, 2004.
79 H. Reichenspurner. Overview of tacrolimus-based immunosuppression after heart or lung transplantation.
J.Heart Lung Transplant. 24 (2):119-130, 2005.
80 S. Hugues, L. Fetler, L. Bonifaz, J. Helft, F. Amblard, and S. Amigorena. Distinct T cell dynamics in lymph nodes during the induction of tolerance and immunity. Nat.Immunol. 5 (12):1235-1242, 2004.
81 T. R. Mempel, S. E. Henrickson, and U. H. Von Andrian. T-cell priming by dendritic cells in lymph nodes
occurs in three distinct phases. Nature 427 (6970):154-159, 2004.
82
J. S. Allan. Immunosuppression for lung transplantation. Semin.Thorac.Cardiovasc.Surg. 16 (4):333-341, 2004.
83 A. Haverich and H. Gorler. Experience with cyclosporine: from revolution to evolution of immunosuppressive protocols in thoracic organ transplantation. Transplant.Proc. 36 (2 Suppl):314S-317S, 2004.
84 A. Azzola, A. Havryk, P. Chhajed, K. Hostettler, J. Black, P. Johnson, M. Roth, A. Glanville, and M. Tamm.
Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplanta-tion. Transplantation 77 (2):275-280, 2004.
85 M. I. Lorber, G. P. Basadonna, A. L. Friedman, K. M. Lorber, M. J. Bia, R. Formica, and J. D. Smith. The evolving role of tor inhibitors for individualizing posttransplant immunosuppression. Transplant.Proc. 33 (7-8):3075-3077, 2001.
86 A. Lorberg, M.N. Hall TOR: The First 10 Years In: G. Thomas, D.M. Salatini “TOR target of rapamycin”
Springer p1-14, 2003.
87 A.D. Hess; P.J.Tutschka; G.W.Santos Effect of Cyclosporin on the induction of cytotoxic T Lymphocytes: Role of interleukin -1 and Interleukin -2 P2248 Anonymous. The First
International Congress on Cyclosporine. May 16-19, 1983, Houston, Texas. Transplant.Proc. 15 (4 Suppl 1-2):2207-3187, 1983
88 R. Lischke, J. Simonek, A. J. Stolz, J. Schutzner, T. Belsan, P. Marusic, and P. Pafko. Cyclosporine-related neurotoxicity in a patient after bilateral lung transplantation for cystic fibrosis. Transplant.Proc. 36 (9):2837-2839, 2004.
89 S.M.Flechner; C. van Buren und weitere „The neprotoxicity of Cyclosporine in Renal Transplant
recipients“ aus Anonymous. The First International Congress on Cyclosporine. May 16-19, 1983,
Houston, Texas. Transplant.Proc. 15 (4 Suppl 1-2):2207-3187, 1983
90 L. Martins, A. Ventura, A. Branco, M. J. Carvalho, A. C. Henriques, L. Dias, A. M. Sarmento, and M. Amil.
Cyclosporine versus tacrolimus in kidney transplantation: are there differences in nephrotoxicity? Trans-plant.Proc. 36 (4):877-879, 2004.
91 N. R. Banner and M. H. Yacoub. Cyclosporine in thoracic organ transplantation. Transplant.Proc. 36 (2 Suppl):302S-308S, 2004.
92 E. R. Garrity, Jr. and M. R. Mehra. An update on clinical outcomes in heart and lung transplantation.
Trans-plantation 77 (9 Suppl):S68-S74, 2004.
93 T. Goto, T. Kino, H. Hatanaka, M. Nishiyama, M. Okuhara, M. Kohsaka, H. Aoki, and H. Imanaka. Discovery
of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant.Proc. 19 (5 Suppl 6):4-8, 1987.
94 E. Mutschler; Gerd Geisslinger. Mutschler Arzneimittelwirkungen. Wissenschaftliche
Verlagsgesellschaft Stuttgard; 8.Aufl., p931-932, 2001
95 RVenkataramanan, V. S. Warty, M. A. Zemaitis, A. T. Sanghvi, G. J. Burckart, H. Seltman, S. Todo, L. Ma-kowka, and T. E. Starzl. Biopharmaceutical aspects of FK-506. Transplant.Proc. 19 (5 Suppl 6):30-35, 1987.
96 M. K. Porayko, T. A. Gonwa, G. B. Klintmalm, and R. H. Wiesner. Comparing nephrotoxicity of FK 506 and cyclosporine regimens after liver transplantation: preliminary results from US Multicenter trial. U.S. Multicen-ter Liver Study Group. Transplant.Proc. 27 (1):1114-1116, 1995.
97
K. Parekh, E. Trulock, and G. A. Patterson. Use of cyclosporine in lung transplantation. Transplant.Proc. 36 (2 Suppl):318S-322S, 2004.
98 M. R. First. Tacrolimus based immunosuppression. J.Nephrol. 17 Suppl 8:S25-S31, 2004.
99 D. Aravot, M. Saute, L. Eidelman, M. Berman, D. Bendayan, B. Orlov, E. Raanani, G. Sahar, A. Kogan, B.
Vidne, and M. Kramer. A new immunosuppressive protocol for lung transplantation: early promising results.
Transplant.Proc. 35 (2):625-626, 2003.
100
G. Izbicki, D. Shitrit, D. Aravot, J. Sulkes, M. Saute, G. Sahar, and M. R. Kramer. Improved survival after lung transplantation in patients treated with tacrolimus/mycophenolate mofetil as compared with cyc-losporine/azathioprine. Transplant.Proc. 34 (8):3258-3259, 2002.
101 H. Jiang, C. Wynn, F. Pan, A. Ebbs, L. M. Erickson, and M. Kobayashi. Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit inter-leukin-10 production. Transplantation 73 (11):1808-1817, 2002.
102
F. Kur, H. Reichenspurner, B. M. Meiser, A. Welz, H. Furst, C. Muller, C. Vogelmeier, M. Schwaiblmaier, J.
Briegel, and B. Reichart. Tacrolimus (FK506) as primary immunosuppressant after lung transplantation. Tho-rac.Cardiovasc.Surg. 47 (3):174-178, 1999.
103 A. Sugioka, M. Morita, T. Kato, S. Hoshimoto, J. Fujita, Z. Morise, and A. Hasumi. FK 506 inhibits tolerance induction in mice liver transplantation. Transplant.Proc. 37 (1):146-147, 2005.
104
J. I. Rodriguez-Barbosa, G. W. Haller, G. Zhao, D. H. Sachs, and M. Sykes. Host thymectomy and cyc-losporine lead to unstable skin graft tolerance after class I mismatched allogeneic neonatal thymic transplanta-tion in mice. Transpl.Immunol. 15 (1):25-33, 2005.
105 C. Knoop, A. Haverich, and S. Fischer. Immunosuppressive therapy after human lung transplantation.
Eur.Respir.J. 23 (1):159-171, 2004.
106 H. Reichenspurner. Overview of tacrolimus-based immunosuppression after heart or lung transplantation.
J.Heart Lung Transplant. 24 (2):119-130, 2005.
107 S. Hugues, L. Fetler, L. Bonifaz, J. Helft, F. Amblard, and S. Amigorena. Distinct T cell dynamics in lymph nodes during the induction of tolerance and immunity. Nat.Immunol. 5 (12):1235-1242, 2004.
108
T. R. Mempel, S. E. Henrickson, and U. H. Von Andrian. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427 (6970):154-159, 2004.
109 D. J. Slebos, H. F. Kauffman, G. H. Koeter, E. A. Verschuuren, W. Bij, and D. S. Postma. Airway cellular
response to two different immunosuppressive regimens in lung transplant recipients. Clin.Transplant. 19 (2):243-249, 2005.
110 M. Fukudo, I. Yano, S. Masuda, M. Okuda, and K. Inui. Distinct inhibitory effects of tacrolimus and cyc-losporin a on calcineurin phosphatase activity. J.Pharmacol.Exp.Ther. 312 (2):816-825, 2005.
111 R. Utsugi, R. N. Barth, R. S. Lee, H. Kitamura, J. C. LaMattina, J. Ambroz, D. H. Sachs, and K. Yamada.
Induction of transplantation tolerance with a short course of tacrolimus (FK506): I. Rapid and stable tolerance to two-haplotype fully mhc-mismatched kidney allografts in miniature swine. Transplantation 71 (10):1368-1379, 2001.
112 M. Kimikawa, D. H. Sachs, R. B. Colvin, A. Bartholomew, T. Kawai, and A. B. Cosimi. Modifications of the conditioning regimen for achieving mixed chimerism and donor-specific tolerance in cynomolgus monkeys.
Transplantation 64 (5):709-716, 1997.
113 Y. Sano, S. Maruyama, M. Aoe, H. Date, and N. Shimizu. Effect of a single injection of high-dose FK506 on lung transplantation in rats. Surg.Today 26 (12):999-1005, 1996.
114 T. Shiraishi, Y. Yasunami, M. Takehara, T. Uede, K. Kawahara, and T. Shirakusa. Prevention of acute lung allograft rejection in rat by CTLA4Ig. Am.J.Transplant. 2 (3):223-228, 2002.
115 A. Boehler and M. Estenne. Obliterative bronchiolitis after lung transplantation. Curr.Opin.Pulm.Med. 6 (2):133-139, 2000.
116 P. Soucek, R. Zuber, E. Anzenbacherova, P. Anzenbacher, and F. P. Guengerich. Minipig cytochrome P450 3A, 2A and 2C enzymes have similar properties to human analogs. BMC.Pharmacol. 1 (1):11, 2001.
117 C. Renard, B. Kristensen, C. Gautschi, V. Hruban, M. Fredholm, and M. Vaiman. Joint report of the first international comparison test on swine lymphocyte alloantigens (SLA). Anim Genet. 19 (1):63-72, 1988.
118 A. D. Kirk. Crossing the bridge: large animal models in translational transplantation research. Immunol.Rev.
196:176-196, 2003.
119 P. Wierup, Q. Liao, R. Bolys, T. Sjoberg, B. Rippe, and S. Steen. Lung edema formation during cold perfu-sion: important differences between rat and porcine lung. J.Heart Lung Transplant. 24 (4):379-385, 2005.
120 T. Wittwer, U. Franke, A. Fehrenbach, D. Meyer, T. Sandhaus, F. Pfeifer, N. Dreyer, T. Mueller, H. Schu-bert, J. Richter, and T. Wahlers. Impact of retrograde graft preservation in Perfadex-based experimental lung transplantation. J.Surg.Res. 117 (2):239-248, 2004.
121 M. Struber, J. M. Hohlfeld, S. Fraund, P. Kim, G. Warnecke, and A. Haverich. Low-potassium dextran solu-tion ameliorates reperfusion injury of the lung and protects surfactant funcsolu-tion. J.Thorac.Cardiovasc.Surg. 120 (3):566-572, 2000.
122
T. Kofidis, M. Struber, G. Warnecke, S. Sommer, R. G. Leyh, L. B. Balsam, R. C. Robbins, and A. Haverich.
Antegrade versus retrograde perfusion of the donor lung: impact on the early reperfusion phase. Transpl.Int.
16 (11):801-805, 2003.
123 M. Struber, J. M. Hohlfeld, T. Kofidis, G. Warnecke, J. Niedermeyer, S. P. Sommer, and A. Haverich. Sur-factant function in lung transplantation after 24 hours of ischemia: advantage of retrograde flush perfusion for preservation. J.Thorac.Cardiovasc.Surg. 123 (1):98-103, 2002.
124 S. Nusair, R. Or, S. Junadi, G. Amir, and R. Breuer. Simultaneous donor marrow cell transplantation with reduced intensity conditioning prevents tracheal allograft obliteration in a bronchiolitis obliterans murine model. Chest 128 (6):4024-4029, 2005.
125 W. Chalermskulrat, K. P. McKinnon, W. J. Brickey, I. P. Neuringer, R. C. Park, D. G. Sterka, B. R. Long, P.
McNeillie, R. J. Noelle, J. P. Ting, and R. M. Aris. Combined donor specific transfusion and anti-CD154 ther-apy achieves airway allograft tolerance. Thorax 61 (1):61-67, 2006.
126 G. Warnecke. Therapie des pulmonalen Ischämie-Repefusionsschaden mit inhaliertem Stickstoffmonoxid und exogenem Surfactant bei Minipigs [dissertation] medizinische Hochschule Hannover; 2002
127 J. M. Morales, A. Andres, B. Dominguez-Gil, M. Arriola, M. J. Gutierrez, E. Hernandez, T. Ortuno, and M.
Praga. Ten years of treatment with tacrolimus is related to an excellent renal function, allowing monotherapy in a large proportion of cases: unicentric results of the tacrolimus versus cyclosporine A European Multicen-tric Study in kidney transplant patients. Transplant.Proc. 37 (9):3738-3742, 2005.
128 M. R. Lucey, M. F. Abdelmalek, R. Gagliardi, D. Granger, C. Holt, I. Kam, G. Klintmalm, A. Langnas, K.
Shetty, A. Tzakis, and E. S. Woodle. A comparison of tacrolimus and cyclosporine in liver transplantation: ef-fects on renal function and cardiovascular risk status. Am.J.Transplant. 5 (5):1111-1119, 2005.
129 T. Shoji, A. Muniappan, D. A. Guenther, J. C. Wain, S. L. Houser, R. Hoerbelt, L. C. Benjamin, R. S. Hasse, M. A. Bravard, D. H. Sachs, J. C. Madsen, and J. S. Allan. Long-term acceptance of porcine pulmonary al-lografts without chronic rejection. Transplant.Proc. 37 (1):72-74, 2005.
130Hans Dieter Volk. Multiparameteranalysen von mononukleären Zelle mittels Durchflußzytometrie.
Helmut Friebe. In: Immunologische Arbeitsmethoden. 4.Aufl.p 324-339, 1991
131 Scheunert, A. and A. Trautmann Laborreferenzwerte Lehrbuch der Veterinärphysiologie. 7. Auflage, Verlag Paul Parey, 1987
132 A. I. Scott, L. D. Sharples, and S. Stewart. Bronchiolitis obliterans syndrome : risk factors and therapeutic strategies. Drugs 65 (6):761-771, 2005.
133 A. B. Cosimi. Calcineurin inhibitors are not antagonistic to tolerance induction. Transplant.Proc. 34 (5):1376-1377, 2002.
134 A. Faro and G. Visner. The use of multiple transbronchial biopsies as the standard approach to evaluate lung allograft rejection. Pediatr.Transplant. 8 (4):322-328, 2004.
135 D. R. Kuypers and Y. C. Vanrenterghem. Tailoring immunosuppressive therapy. Nephrol.Dial.Transplant. 17 (12):2051-2054, 2002.
136 A. Zuckermann, W. Klepetko, T. Birsan, S. Taghavi, O. Artemiou, W. Wisser, G. Dekan, and E. Wolner.
Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation. J.Heart Lung Transplant. 18 (5):432-440, 1999.
137 K. McNeil, A. R. Glanville, T. Wahlers, C. Knoop, R. Speich, R. D. Mamelok, J. Maurer, J. Ives, and P. A.
Corris. Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syn-drome in de novo lung transplant recipients. Transplantation 81 (7):998-1003, 2006.
138 S. Vitko and O. Viklicky. Cyclosporine renal dysfunction. Transplant.Proc. 36 (2 Suppl):243S-247S, 2004.
139 D. C. Wright, H. S. Deol, and B. E. Tuch. A comparison of the sensitivity of pig and human peripheral blood mononuclear cells to the antiproliferative effects of traditional and newer immunosuppressive agents.
Transpl.Immunol. 7 (3):141-147, 1999.
140 S. Metcalfe, R. Svvennsen, and R. Y. Calne. FK506 and rapamycin: differential sensitivity of human, baboon, cynomolgus monkey, dog and pig lymphocytes. Transpl.Int. 5 Suppl 1:S514-S515, 1992.
141 D. A. Hesselink, R. H. van Schaik, der Heiden van, I, Werf M. van der, P. J. Gregoor, J. Lindemans, W.
Weimar, and T. van Gelder. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and phar-macokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin.Pharmacol.Ther. 74 (3):245-254, 2003.
142 H. Zheng, A. Zeevi, E. Schuetz, J. Lamba, K. McCurry, B. P. Griffith, S. Webber, J. Ristich, J. Dauber, A.
Iacono, W. Grgurich, D. Zaldonis, K. McDade, J. Zhang, and G. J. Burckart. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J.Clin.Pharmacol. 44 (2):135-140, 2004.
143 B. M. Frey, M. Sieber, D. Mettler, H. Ganger, and F. J. Frey. Marked interspecies differences between hu-mans and pigs in cyclosporine and prednisolone disposition. Drug Metab Dispos. 16 (2):285-289, 1988.
144 A. Dhawan, J. M. Tredger, P. J. North-Lewis, C. E. Gonde, A. P. Mowat, and N. J. Heaton. Tacrolimus (FK506) malabsorption: management with fluconazole coadministration. Transpl.Int. 10 (4):331-334, 1997.
145 M. H. Kapturczak, H. U. Meier-Kriesche, and B. Kaplan. Pharmacology of calcineurin antagonists. Trans-plant.Proc. 36 (2 Suppl):25S-32S, 2004.
146 S. A. Yousem, G. J. Berry, P. T. Cagle, D. Chamberlain, A. N. Husain, R. H. Hruban, A. Marchevsky, N. P.
Ohori, J. Ritter, S. Stewart, and H. D. Tazelaar. Revision of the 1990 working formulation for the classifica-tion of pulmonary allograft rejecclassifica-tion: Lung Rejecclassifica-tion Study Group. J.Heart Lung Transplant. 15 (1 Pt 1):1-15, 1996.
147 M. D. Pescovitz, J. K. Lunney, and D. H. Sachs. Preparation and characterization of monoclonal antibodies reactive with porcine PBL. J.Immunol. 133 (1):368-375, 1984.
148 E. Suri-Payer, A. Z. Amar, A. M. Thornton, and E. M. Shevach. CD4+CD25+ T cells inhibit both the induc-tion and effector funcinduc-tion of autoreactive T cells and represent a unique lineage of immunoregulatory cells.
J.Immunol. 160 (3):1212-1218, 1998.
149 D. Delia, E. Martinez, E. Fontanella, and A. Aiello. Two- and three-color immunofluorescence using amino-coumarin, fluorescein, and phycoerythrin-labelled antibodies and single laser flow cytometry. Cytometry 12 (6):537-544, 1991.
150 H. Treede, W. Klepetko, H. Reichenspurner, A. Zuckermann, B. Meiser, T. Birsan, W. Wisser, and B. Rei-chert. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. J.Heart Lung Transplant. 20 (5):511-517, 2001.
151 L. D. Sharples, K. McNeil, S. Stewart, and J. Wallwork. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J.Heart Lung Transplant. 21 (2):271-281, 2002.
152 M. Crespo, M. Pascual, N. Tolkoff-Rubin, S. Mauiyyedi, A. B. Collins, D. Fitzpatrick, M. L. Farrell, W. W.
Williams, F. L. Delmonico, A. B. Cosimi, R. B. Colvin, and S. L. Saidman. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 71 (5):652-658, 2001.
153 K. Wiebe, W. Harringer, U. Franke, M. Struber, N. Krug, F. Korff, T. Wahlers, J. Cremer, and A. Haverich.
FK506 rescue therapy in lung transplantation. Transplant.Proc. 30 (4):1508-1509, 1998.
154 H. G. Fieguth, S. Krueger, D. E. Wiedenmann, I. Otterbach, and T. O. Wagner. Tacrolimus for treatment of
154 H. G. Fieguth, S. Krueger, D. E. Wiedenmann, I. Otterbach, and T. O. Wagner. Tacrolimus for treatment of